This website uses cookies to ensure you get the best experience on our website.
Visit our privacy policy for more information.
We are a clinical stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around plasma gelsolin technology and therapeutics. With our ability to provide a platform to replete plasma gelsolin that has been depleted, we are in a unique position to deliver therapeutics that have the potential to disrupt the way many diseases are treated today.
PATENTS
COLLABORATORS
MARKET POTENTIAL
Chronic inflammation plays a central role in some of the most challenging diseases of our time. Restoring the body with a recombinant version of a naturally occurring plasma protein – plasma gelsolin — that becomes depleted in diverse infectious and non-infectious diseases has enormous potential to prevent debilitating and potentially lethal ravages of inflammation without compromising its essential function to fight infection and promote repair. This strategy has consistently reduced morbidity and mortality of animals challenged with acute infections, traumatic and chemical injuries, autoimmune disorders and with insults associated with chronic illnesses.
LOCATION:
BioAegis Therapeutics
North Brunswick, NJ
MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com
INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com
©2020 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use
This website uses cookies to ensure you get the best experience on our website.
Visit our privacy policy for more information.